iRadimed Corporation $IRMD Shares Sold by Copeland Capital Management LLC

Copeland Capital Management LLC lessened its stake in iRadimed Corporation (NASDAQ:IRMD) by 12.9% during the 1st quarter, HoldingsChannel reports. The firm owned 359,325 shares of the medical equipment provider’s stock after selling 53,225 shares during the quarter. Copeland Capital Management LLC’s holdings in iRadimed were worth $34,589,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also bought and sold shares of IRMD. T. Rowe Price Investment Management Inc. increased its holdings in shares of iRadimed by 410.7% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 255,887 shares of the medical equipment provider’s stock valued at $24,893,000 after purchasing an additional 205,783 shares in the last quarter. Goldman Sachs Group Inc. lifted its stake in shares of iRadimed by 37.0% in the 4th quarter. Goldman Sachs Group Inc. now owns 205,227 shares of the medical equipment provider’s stock valued at $19,964,000 after purchasing an additional 55,426 shares during the period. Informed Momentum Co LLC purchased a new stake in iRadimed during the fourth quarter worth $5,361,000. SG Americas Securities LLC grew its position in iRadimed by 88.6% during the fourth quarter. SG Americas Securities LLC now owns 70,391 shares of the medical equipment provider’s stock valued at $6,848,000 after buying an additional 33,072 shares during the period. Finally, Invesco Ltd. grew its position in iRadimed by 473.9% during the fourth quarter. Invesco Ltd. now owns 35,131 shares of the medical equipment provider’s stock valued at $3,418,000 after buying an additional 29,010 shares during the period. Hedge funds and other institutional investors own 92.34% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have weighed in on IRMD. Weiss Ratings downgraded shares of iRadimed from a “buy (b)” rating to a “buy (b-)” rating in a research report on Wednesday, May 20th. Freedom Capital raised shares of iRadimed to a “strong-buy” rating in a research note on Thursday, April 2nd. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $120.00.

Insider Transactions at iRadimed

In other news, CEO Roger E. Susi sold 5,000 shares of iRadimed stock in a transaction dated Monday, April 20th. The shares were sold at an average price of $93.36, for a total value of $466,800.00. Following the sale, the chief executive officer owned 2,205,000 shares in the company, valued at $205,858,800. This trade represents a 0.23% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 32,500 shares of company stock worth $2,864,903 over the last quarter. Company insiders own 34.60% of the company’s stock.

iRadimed Price Performance

iRadimed stock opened at $97.03 on Friday. The stock has a market capitalization of $1.24 billion, a PE ratio of 53.02 and a beta of 0.90. The business has a 50 day simple moving average of $93.23 and a 200-day simple moving average of $95.94. iRadimed Corporation has a 12 month low of $55.11 and a 12 month high of $107.90.

iRadimed (NASDAQ:IRMD) last announced its earnings results on Friday, May 1st. The medical equipment provider reported $0.49 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.46 by $0.03. iRadimed had a return on equity of 24.48% and a net margin of 27.36%.The firm had revenue of $21.98 million for the quarter, compared to analyst estimates of $21.32 million. iRadimed has set its FY 2026 guidance at 2.060-2.210 EPS and its Q2 2026 guidance at 0.440-0.480 EPS. On average, equities research analysts anticipate that iRadimed Corporation will post 1.52 EPS for the current fiscal year.

iRadimed Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, May 29th. Shareholders of record on Friday, May 15th were given a dividend of $0.20 per share. The ex-dividend date was Friday, May 15th. This represents a $0.80 dividend on an annualized basis and a yield of 0.8%. iRadimed’s dividend payout ratio is currently 43.72%.

iRadimed Profile

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.